Switch to
More onapp

Suven Life Sciences Ltd

SUVEN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,391 cr, stock is ranked 935
Moderate RiskStock is 2.62x as volatile as Nifty
63.100.45 (-0.71%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,391 cr, stock is ranked 935
Moderate RiskStock is 2.62x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-11.41
PB RatioPB Ratio
14.47
Dividend YieldDiv. Yield
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Suven Life Sciences Limited is a pharmaceutical company engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. It provides a range of Drug Discovery and Development Support Services (DDDSS). The Company offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

Financial TrendFinancial statements 

2019202020212022312.9228.4521.2317.16-23.90-94.22-72.16-121.99
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Newspaper Advertisements 
Announced OnNov 23, 2022

Suven Life Sciences Limited has informed the Exchange about Newspaper Advertisements - Post Rights Issue | Download

Suven Life Sciences Limited has informed the Exchange about Newspaper Advertisements - Post Rights Issue | Download

Related Party Transaction 
Announced OnNov 22, 2022

Suven Life Sciences Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Suven Life Sciences Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Cash Dividend 
Ex. DateFeb 17, 2021

Interim • Div/Share: ₹ 1

See all events